Memantine Receives Tentative FDA Nod, Says Wockhardt

by Rajshri on  January 7, 2010 at 9:36 PM Corporate News   - G J E 4
 Memantine Receives Tentative FDA Nod, Says Wockhardt
Wockhardt Limited has announced that it has received tentative approval from the US Food and Drug Administration for marketing market Memantine tablets in the strength of 5 mg and 10 mg. Memantine is used in the treatment of Alzheimer`s disease.

The drug works by suppressing N-Methyl-D-Aspartate (NMDA) receptors, which are thought to be responsible for the deterioration of cholinergic cells in the brain.

On December 29, Wockhardt had revealed that its preferential issue would not exceed 1.6 billion convertible or non-convertible redeemable preference shares worth Rs 5 each.

Source: Medindia

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like